Author:
Kumon Kazuki,Afify Said M.,Hassan Ghmkin,Ueno Shunsuke,Monzur Sadia,Nawara Hend M.,Quora Hagar A. Abu,Sheta Mona,Xu Yanning,Fu Xiaoying,Zahra Maram H.,Seno Akimasa,Seno Masaharu
Abstract
AbstractCancer stem cells (CSCs) are subpopulations in the malignant tumors that show self-renewal and multilineage differentiation into tumor microenvironment components that drive tumor growth and heterogeneity. In previous studies, our group succeeded in producing a CSC model by treating mouse induced pluripotent stem cells. In the current study, we investigated the potential of CSC differentiation into blood cells under chemical hypoxic conditions using CoCl2. CSCs and miPS-LLCcm cells were cultured for 1 to 7 days in the presence of CoCl2, and the expression of VEGFR1/2, Runx1, c-kit, CD31, CD34, and TER-119 was assessed by RT-qPCR, Western blotting and flow cytometry together with Wright-Giemsa staining and immunocytochemistry. CoCl2 induced significant accumulation of HIF-1α changing the morphology of miPS-LLCcm cells while the morphological change was apparently not related to differentiation. The expression of VEGFR2 and CD31 was suppressed while Runx1 expression was upregulated. The population with hematopoietic markers CD34+ and c-kit+ was immunologically detected in the presence of CoCl2. Additionally, high expression of CD34 and, a marker for erythroblasts, TER-119, was observed. Therefore, CSCs were suggested to differentiate into erythroblasts and erythrocytes under hypoxia. This differentiation potential of CSCs could provide new insight into the tumor microenvironment elucidating tumor heterogenicity.
Funder
Young Scientists
JSPS Grant-in-Aid for Scientific Research
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Wakao, F. et al. Cancer statistics in Japan – 2019 (eds. Wakao, F. et al.) 4–137 (Foundation for Promotion of Cancer Research, 2020).
2. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7–34 (2019).
3. Afify, S. M. & Seno, M. Conversion of stem cells to cancer stem cells: undercurrent of cancer initiation. Cancers (Basel). 11, 345 (2019).
4. Phi, LTH. et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018, 5416923 (2018).
5. Pattabiraman, D. R. & Weinberg, R. A. Tackling the cancer stem cells - what challenges do they pose?. Nat. Rev. Drug Discov. 13, 497–512 (2014).
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献